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Purpose: We have previously shown that High Density Lipoprotein (HDL) 
signifi cantly reduced ex vivo ischemia/reperfusion (IR) -induced cell death. This 
HDL-induced cardioprotection involved phosphorylation of connexin43 (Cx43) gap 
junction channels resulting in reduced cell-to-cell diffusion of large molecules while 
cardiac conduction was preserved. Here, we investigate whether the cardioprotective 
properties of HDL on Cx43 gap junctions are conferred by sphingosine-1-phosphate 
(S1P).
Methods and Results: Neonatal rat cardiomyocytes (NRC) were treated for 5 
min with HDL or S1P after pre-incubation with specifi c antagonists of S1P receptors. 
We found by Western blot that S1P induced phosphorylation of Cx43 on Serine 368 
(Cx43-S368) by a PKC-dependent mechanism, an effect similar to the one previously 
shown for HDL. In addition, S1P-induced phosphorylation of Cx43 was mediated by 
S1P2 and S1P3, but not by S1P1, receptors. Moreover, endogenous production of S1P 
stimulated by ganglioside GM-1 also increased Cx43-S368 phosphorylation in NRC. 
Interestingly, ex vivo Langendorff heart perfusion showed that, similar to HDL, 5 min 
S1P treatment at the onset of reperfusion signifi cantly reduced infarct size in response 
to 30 min of no-fl ow global ischemia (control: 23±3%, S1P-treated: 11±2%, p<0.05). 
To investigate the cardioprotective role of S1P in vivo, we have used ApoM transgenic 
(Apom-Tg) and ApoM-knockout (Apom-/-) mice in which plasma S1P is increased 
by about 265% and decreased by 45%, respectively. We have found a signifi cant 
reduction in vivo of infarct size after 30 min of left coronary artery ligation and 24 
hours reperfusion in Apom-Tg (15±1% (n=7) compared with wild type mice (29±4% 
(n=9), p<0.01). and no effect on the infarct size in Apom-/- mice d (33±6%, n=9).
Conclusion: Short-term treatment with HDL modifi es Cx43 gap junction channels 
by activation of S1P pathways. Interestingly, an increase of plasma apoM and S1P in 
mice favored cardioprotection after IR. 
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A new method for long-term (16 hours) hypothermic preservation of cardiac 
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One of the main problems encountered in heart transplantation is the limited 
preservation time of the donor heart, commonly less than 6 hours. Long-term preservation 
would allow transport for long distance and adequate time for transplant assessment. 
In order to increase this preservation time, a simple, portable and reliable equipment 
for graft perfusion has been conceived and patented. This system allows pulsatile 
transplant microperfusion at 4°C during which the heart tissue is simultaneously 
perfused (during the imitated diastolic phase) and massed (during the imitated systolic 
phase). To evaluate functionality of this system, feasibility tests were performed on 
isolated pig heart (n=12). After harvesting, heart were preserved 16 hours in cold 
cardioplegic medium (St. Thomas’ Hospital solution) either by simple storage (control 
group) or pulsatile microperfusion. Hypothermic heart preservation was followed by 
reperfusion, performed on an ex-vivo functional testing system at the end of the cold 
period. Preliminary investigations demonstrated good viability and functionality of the 
hearts preserved with this new hypothermic perfusion apparatus. These encouraging 
preclinical results allow to envisage a future clinical use. 
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Paracrine factors from cardiac fi broblasts protect cardiomyocytes against 
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Cardiac fi broblasts (CF) are the largest cell population in the heart. They are 
involved in physiological and pathological processes like heart failure and remodelling. 
We hypothesize that CF may also be implicated in the modulation of cardiopro-
tection during the acute phase of ischemia reperfusion (I/R) injury. 
Cardiomyocytes (CM) were isolated from 2 days old Wistar rats and submitted to 
3 hours of hypoxia, followed by 21 hours of reoxygenation. Conditioned medium of CF 
was produced inducing 3 hours of hypoxia on CF and supernatant was collected just after 
hypoxia. Cytokine array was used to detect factors present in CF conditioned medium 
and TIMP-1 (Tissue Inhibitor of Metalloproteinase 1) was the most highly expressed 
factor. CM were treated with conditioned medium or TIMP-1 (0,5nM) at reperfusion. 
After hypoxia reoxygenation (H/R), cell mortality was evaluated using MTT assay and 
fl ow cytometry by Annexin V and propidium iodide staining assay. Western blots were 
performed in order to detect Akt and ERK1/2 proteins and their phosphorylated forms. 
LY24002 and PD98059 were used as inhibitors to investigate PI3K/Akt and ERK1/2 
signalling pathway respectively. In vivo experiments were performed on C57Bl6 mice by 
coronary artery ligation during 60 minutes through a left thoracotomy. Animals received 
5 minutes before reperfusion an i.v bolus of drug vehicle or conditioned medium of CF 
or TIMP-1 (1 μg/kg). Areas at risk and areas of necrosis were evaluated after 24 hours of 
reperfusion by TTC staining.
We showed that conditioned medium of CF decreased CM mortality after H/R 
in vitro and decreased infarct size in vivo after mice I/R. TIMP-1 alone decreased CM 
mortality after H/R and induced an activation of Akt and ERK1/2 signalling pathway. Akt 
and ERK1/2 inhibitors reversed this protecting effect. In vivo experiments showed that 
TIMP-1 reduced infarct size by 25% vs control. 
Our data suggest, that CF are able to protect CM after I/R in a paracrine way, 
mediated in part by TIMP-1, which decreased mortality of CM and reduced infarct 
size after I/R injury. This protection may be due to an anti-apoptotic effect of TIMP-1 
and could be mediated by an activation of Akt and ERK1/2 signalling pathways. 
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and oxidative stress; compliance, endothelial function and the structural wall of the 
carotid artery were only altered after a longer IH exposure. Atorvastatin prevented all 
these deleterious cardiovascular effects, leading to a potentially novel pharmacological 
therapeutic strategy for OSA syndrome.
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Regulation of eADA (ecto-Adenosine deaminase) by hypoxia in the developing 
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Fabrice Marcillac, Elodie Robin, Eric Raddatz
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Adenosine is an important regulator of the developing cardiovascular system and 
its production is increased by hypoxia/ischemia. In the present study, we used the 
4-day-old chick embryonic heart model to explore the molecular regulation by real 
time PCR of 1) adenosinergic signaling pathway and 2) the adenosine transporters 
after exposure to hypoxia (10% O2). We also dissected the spatial expression of each 
target gene in atria, ventricle and outfl ow tract.
Amongst the adenosine transporters detected (ENT1, 3, 4 and CNT3), ENT1 
was the most expressed equally in the different parts of the heart, and its expression 
was not modulated by hypoxia. We determined the expression of enzymes involved 
in adenosine production: CD39 (nucleoside triphosphate dephosphorylase) and CD73 
(5’-ectonucleotidase), as well as the enzyme responsible for its degradation into 
inosine i.e. eADA (ecto-adenosine deaminase). Interestingly, eADA was strongly 
down-regulated by hypoxia, especially in the atria. As expected, adenosine and inosine 
levels increased after hypoxia.
These results suggest that eADA plays a crucial role in the adaptive response 
that could protect heart against a hypoxic stress.
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Irreversible reperfusion injury is due to apoptotic cell death after acute myocardial 
infarction (AMI). DAXX (death-associated protein) appears to be essential for 
transducing the FAS-dependent apoptotic signal in vivo. The aim of our study was to 
test the possibility to decouple the FAS-DAXX interaction with a peptidic inhibitor 
in order to decrease infarct size.
Peptides inhibiting the Fas – DAXX interaction (DAXXp) have been engineered 
using the SPOT synthesis strategy. When coupled to cell penetrating peptides, 
DAXXp was taken up by cultured cardiomyocytes and inhibited apoptosis by 
approximately 50% in vitro. C57BL/6J mice were subjected to 40 min ischemia/1h 
or 24 h -reperfusion in vivo. Area at risk and infarct size were measured after 
dual staining by phthalocyanine blue dye and 2,3,5-triphenyltetrazolium chloride. 
Apoptosis was measured in the ischemic versus the non-ischemic part of the left 
ventricle by DNA fragmentation assay and caspase-3 activity.
CPP-DAXXp, administered as a single bolus 5 min before myocardial reperfusion, 
decreased by 59% both infarct size and apoptosis in our in vivo model of myocardial IR 
injury. Cardioprotection was associated with a 59%-decrease in post-infarction mortality 
in the early 24 h of reperfusion. Dose-response curves showed that cardioprotection 
was maximal at 1 mg/kg and SPECT-SCAN analysis revealed that elimination was 
completed 24 h after injection. Interestingly, a 30 min-therapeutical time window of 
cardioprotection was available for the CPP-DAXXp peptidic strategy. 
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Introduction: Therapeutic hypothermia (TH) is the only adjuvant therapy of 
cardio-pulmonary resuscitation to have proven its effi ciency following a resuscitated 
cardiac arrest (CA). CA might initiate cell death at resuscitation via the opening of a 
mega-canal called mitochondrial permeability transition pore (mPTP). We endeavored 
to study the mitochondrial effects of TH in an experimental CA model.
Materials and Methods: NZW rabbits were subjected to a 15 minute period of 
hypoxic CA followed by resuscitation (cardiac massage, resumption of ventilation, 
epinephrine) and 120 minutes of reperfusion. Three groups of animals (n=8/group) 
were studied: Sham; Control (Ctrl); TH, CA with fast hypothermia (15 min) induced 
by external cooling at reperfusion (target temperature: 32°C). The following measu-
rements were carried out: invasive hemodynamics, echocardiography, cell damage 
markers (lactate, troponin I, ALT, creatinine, NSE), measurement of the calcium 
retention capacity (CRC), i.e. the Ca2+ load required for mPTP opening, and oxidative 
phosphorylation on mitochondria isolated from both cerebral cortex and myocardium.
Results: The characteristics of animals and CA were similar among groups. The 
arterial blood pressure and the left ventricular shortening fraction, both altered by CA, 
were improved by TH in comparison with the Ctrl group (p<0.05). Cellular damages 
were prevented by TH (p<0.05 versus Ctrl). TH improved the CRC (altered, by CA): 
+72% in the brain and +53% in the myocardium (p<0.05 versus Ctrl). TH also improved 
the ADP-stimulated mitochondrial respiration in the brain (p<0.05 versus Ctrl).
Conclusions: These results suggest that TH might limit multiple organ failure 
following resuscitated CA by preventing mitochondrial dysfunction (mPTP opening 
and oxidative phosphorylation). 
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Atorvastatin protects against deleterious cardiovascular consequences 
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Chronic intermittent hypoxia (IH), a major component of obstructive sleep apnea 
(OSA) contributes to the high risk of cardiovascular morbidity. We have previously 
demonstrated that IH-induced oxidative stress is involved in the hypertension and in 
the hypersensitivity to myocardial infarction. However, the mechanisms underlying 
these cardiovascular alterations are still unclear, as well as the role of potential 
protective treatment. Atorvastatin has pleiotropic actions, including increasing NO 
bioavailability and reducing infl ammation and oxidative damage. The aim of this 
study was to evaluate the benefi cial effect of a two time course of this treatment 
against the deleterious cardiovascular consequences of IH. Rats were divided 
into two groups subjected to chronic IH or normoxic (N) exposure. IH consisted 
of repetitive 1-min cycles (with only 30 s of a 5% inspired O2 fraction) and was 
applied for 8 h during daytime, for 14- (preventive protocol) or 28-days (curative 
protocol). Atorvastatin (10 mg.kg-1.day-1) or its vehicle was administered during 
the 14-days preventive protocol or the last 14 days of the curative protocol. For 
both protocols, systolic arterial pressure was signifi cantly increased by 14-days IH 
exposure. Atorvastatin prevented this deleterious effect in the preventive protocol. 
Carotid artery compliance and endothelial function were signifi cantly altered after 
28-days but not after 14-days of IH exposure. Curative atorvastatin administration 
preserved these vascular parameters. IH also increased hypersensitivity to myocardial 
infarction after 14-days exposure, and atorvastatin abolished this deleterious effect. 
IH also enhanced cardiac NADPH expression and decreased aortic SOD activity after 
14-days exposure. Atorvastatin signifi cantly restored these activities. In conclusion, 
whereas IH rapidly increased blood pressure, myocardial infarction hypersensitivity 
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Myocardial infarction (MI) is the major cause of cardiovascular mortality in 
western countries. Reperfusion as early as possible is the only treatment recognized 
to reduce infarct size, crucial prognostic factor of morbidity and mortality. However, 
reperfusion leads to ischemia-reperfusion (IR) injury leading to irreversible apoptotic 
death of cardiomyocytes. A transcriptomic approach has allowed us to identify genes 
specifi cally regulated upon ischemic postconditioning (PostC) in the mouse heart. 
Among them, the expression of the metabotropic glutamate receptor type 1 (mGluR1) 
gene is up-regulated by PostC. 
The aim of this study was to investigate the role of mgluR1 during myocardial 
IR. Using mgluR1 knockout mice we confi rmed the involvement of mgluR1 in 
cardioprotection. Using real-time quantitative PCR and immunolabeling, our study 
reveals that ischemic postconditioning stimulus was associated with up-regulation 
of mgluR1 expression both at the transcriptional and protein levels in mouse hearts in 
vivo. In C57Bl6 mice, injection of glutamate at the time of reperfusion signifi cantly 
reduced infarct size (45% decrease) via apoptosis inhibition. This cardioprotective 
effect was reduced in presence of the specifi c antagonist YM 298198 or in presence 
of wortmannin, an inhibitor of PI3-kinase, which is activated downstream mgluR1. 
In our mouse model of myocardial IR injury, decrease in infarct size after glutamate 
treatment seems to be associated to an improved left ventricular contractile function 
assessed by echocardiography 15 days post-infarction (speckle tracking method 
quantifying myocardial strain). All together these results suggest that mgluR1 
activation through PI3-kinase-AKT pathway plays an important role in cardioprotection 
against ischemia-reperfusion injury.
Our study clearly indicates that DAXXp conjugate contributes to cardioprotection 
in vivo when injected intravenously at a single low-dose during the fi rst minutes of 
reperfusion by inhibiting ischemia/reperfusion induced apoptosis. Importantly, the 
therapeutical time window extended up to 30 min to treat myocardial infarction. 
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